


**Product Name** : KME-2780  
**Cat. No.** : PC-21201  
**CAS No.** : 2968466-26-2  
**Molecular Formula** : C<sub>20</sub>H<sub>23</sub>N<sub>5</sub>  
**Molecular Weight** : 333.44  
**Target** : IRAK  
**Solubility** : 10 mM in DMSO



CAS: 2968466-26-2

## Biological Activity

KME-2780 (KME2780) is a potent and selective dual IRAK1 and IRAK4 (**IRAK1/4**) inhibitor with IC<sub>50</sub> of 19 and 0.5 nM, respectively.

KME-2780 shows K<sub>d</sub> values of 2.2 and 0.2 nM for IRAK1 and IRAK4, respectively.

KME-2780 is significantly more effective at suppressing TLR2-mediated activation of NF-κB and autophosphorylation of IRAK1 in AML cells as compared with the IRAK4 selective inhibitor KME-3859.

KME-2780 downregulates genes in MAPK/AP1, ATF4, IGF1R, and EGFR signaling in AML cells.

KME-2780 suppresses leukemia stem/progenitor cells (LSPCs), suppresses OCI-AML3 cells, which is insensitive to the genetic inactivation of IRAK1 and IRAK4.

KME-2780 treatment also resulted in a greater expression of CD38, a glycoprotein expressed on mature immune cells.

KME-2780 (30 mg/kg, orally daily) suppresses MDS/AML in xenografted mice.

## References

Bennett J, et al. *Blood*. 2023 Sep 14;142(11):989-1007.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com